The Y606C RET mutation causes a receptor gain of function

Clinical Endocrinology

Volumn 69, Issue 2, 2008, Pages 253-258

  Ercolino, T ^a   Lombardi, A ^a   Becherini, L ^a   Piscitelli, E ^a   Cantini, G ^a   Gagliano M S ^a   Serio, M ^a   Luconi, M ^a   Mannelli, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN RET; TYROSINE;

ADULT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVITY; EXON; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MISSENSE MUTATION; MOLECULAR CLONING; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RET GNEE; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; THYROID MEDULLARY CARCINOMA; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; CARCINOMA, MEDULLARY; CYSTEINE; FEMALE; GERM-LINE MUTATION; HUMANS; MICE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; TYROSINE;

EID: 47549086949     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03197.x     Document Type: Article

References (20)

1. Takahashi, M., Buma, Y., Iwamoto, T., Inaguma, Y., Ikeda, H. Hiai, H. (1988) Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene, 3, 571 578.
2. Santoro, M., Rosati, R., Grieco, M., Berlingieri, M.T., D'Amato, G.L., de Franciscis, V. Fusco, A. (1990) The RET proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene, 5, 1595 1598.
3. Manie, S., Santoro, M., Fusco, A. Billaud, M. (2001) The RET receptor: function in development and dysfunction in congenital malformation. Trends in Genetics, 17, 580 589.
4. Airaksinen, M.S. Saarma, M. (2002) The GDNF family: signalling, biological functions and therapeutic value. Nature Review in Neuroscience, 3, 383 394.
5. Jing, S. Wen, D., Yu, Y., Holst, P.L., Luo, Y., Fang, M., Tamir, R., Antonio, L., Hu, Z., Cupples, R., Louis, J.C., Hu, S., Altrock, B.W. Fox, G.M. (1996) GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell, 85, 1113 1124.
6. Santoro, M., Carlomagno, F., Romano, A., Bottaro, D.P., Dathan, N.A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M.H. Di Fiore, P.P. (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science, 267, 381 383.
7. Eng, C., Clayton, D., Schuffenecker, I., Lenoir, G., Cote, G., Gagel, R.F., van Amstel, H.K., Lips, C.J., Nishisho, I., Takai, S.I., Marsh, D.J., Robinson, B.G., Frank-Raue, K., Raue, F., Xue, F., Noll, W.W., Romei, C., Pacini, F., Fink, M., Niederle, B., Zedenius, J., Nordenskjold, M., Komminoth, P., Hendy, G.N. Mulligan, L.M. (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Journal of the American Medical Association, 276, 1575 1579.
8. Brandi, M.L., Gagel, R.F., Angeli, A., Bilezikian, J.P., Beck-Peccoz, P., Bordi, C., Conte-Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J., Lombardi, G., Mannelli, M., Pacini, F., Ponder, B.A., Raue, F., Skogseid, B., Tamburrano, G., Thakker, R.V., Thompson, N.W., Tomassetti, P., Tonelli, F., Wells, S.A. Jr. Marx, S.J. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinoogy and Metabolism, 86, 5658 5671.
9. Machens, A., Niccoli-Sire, P., Hoegel, J., Frank-Raue, K., van Vroonhoven, T.J., Roeher, H.D., Wahl, R.A., Lamesch, P., Raue, F., Conte-Devolx, B., Dralle, H. European Multiple Endocrine Neoplasia (EUROMEN) Study Group (2003) Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine, 349, 1517 1525.
10. Santoro, M., Melillo, R.M., Carlomagno, F., Vecchio, G.C. Fusco, A. (2004) Minireview: RET: normal and abnormal functions. Endocrinology, 145, 5448 5451.
11. Mulligan, L.M., Eng, C., Healey, C.S., Clayton, D., Kwok, J.B., Gardner, E., Ponder, M.A., Frilling, A., Jackson, C.E., Lehnert, H., Hartmut, N.H., Thibodeau, M.A. Ponder, B.A. (1994) Specific mutation of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics, 6, 70 74.
12. Takahashi, M. (1995) Oncogenic activation of the RET proto-oncogene in thyroid cancer. Critical Reviews in Oncogenesis, 6, 35 46.
13. Takahash i, M., Asai, N., Iwashita, T., Murakami, H. Ito, S. (1998) Molecular mechanism of development of multiple endocrine neoplasia 2 by RET mutations. Journal of International Medicine, 43, 509 513.
14. Kwok, B.J., Gardner, E., Warner, J.P., Ponder, B.A. Mulligan, L.M. (1993) Structure analysis of the human RET proto-oncogene using exon trapping. Oncogene, 8, 2575 2582.
15. Ahmed, A.S., Snow-Bailey, K., Highsmith, W.E., Sun, W., Fenwick, R.G. Mao, R. (2005) Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases. Journal of Molecular Diagnostics, 7, 283 288.
16. Orgiana, G., Pinna, G., Camedda, A., De Falco, V., Santoro, M., Melillo, R.M., Elisei, R., Romei, C., Lai, S. Carcassi, C. (2004) A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure. Journal of Clinical Endocrinology and Metabolism, 89, 4810 4816.
17. Carlomagno, F., Salvatore, G., Cirafici, A.M., De Vita, G., Melillo, R.M., de Franciscis, V., Billaud, M., Fusco, A. Santoro, M. (1997) The different RET-activating capability of mutations of Cysteine 620 or Cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype. Cancer Research, 57, 391 395.
18. Arlt, D.H., Baur, B., Wagner, B. Hoppner, W. (2000) A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation. Oncogene, 19, 3445 3448.
19. Lu, X., Gross, A.W. Lodish, H.F. (2006) Active conformation of the erytropoietin receptor. Random and cysteine scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. Journal of Biological Chemistry, 281, 7002 7011.
20. Chappuis-Flament, S., Pasini, A., De Vita, G., Segouffin-Cariou, C., Fusco, A., Attiè, T., Lenoir, G.M., Santoro, M. Billaud, M. (1998) Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmatic cysteines. Oncogene, 17, 2851 2861.